Intellia Therapeutics, Inc.

Entry into a Material Definitive Agreement. Intellia Therapeutics, Inc. (the “Company”) previously entered into an Open Market Sale Agreement, dated March 4, 20

, including Exhibit 99.2 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise su

. Other Events. On March 2, 2026, Intellia announced that the U.S. Food and Drug Administration (“FDA”) has removed the clinical hold on the investigational new

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Goodwin Procter LLP 99.1 Amendment No. 2 to the Open Market Sale Agreemen